Drug developer Pfizer Inc. announced on Tuesday that they have tide up with a five year deal with Bausch & Lomb- to co-promote prescription eye-care drugs in the United States of America.
Pfizer Ophthalmics discovers, develops and provides leading treatments in ophthalmology to support patients who are at risk of blindness or suffering from vision impairment, and to serve the health care professionals who treat them.
Bausch & Lomb is one of the best-known and most respected healthcare brands in the world. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals.
Financial terms of the five-year deal were not disclosed. The partnership includes :-
Pfizer's Xalatan® (latanoprost ophthalmic solution)
and Bausch & Lomb’s Alrex® (loteprednol etabonate ophthalmic suspension 0.2%),
Lotemax® (loteprednol etabonate ophthalmic suspension 0.5%)
and Zylet® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension).
The co-promotion agreement also will apply to Bausch & Lomb’s investigational anti-infective eye drop, besifloxacin ophthalmic suspension, 0.6%, which is currently under review by the U.S. Food and Drug Administration (FDA).
Meanwhile, Pfizer said it will continue to maintain their three mid stage developing eye-care products separate from the partnership.
The eye-care announcement follows New York-based Pfizer's move to begin selling dozens more generic drugs in the U.S. and Europe through new deals with Indian generic company Aurobindo Pharma Ltd.
We are really looking forward to experience the synergistic effects which are highly expected from the combine efforts of the two top listed eye care specialists. But if others agree with me what I feel like that along with the rising curve of Pfizer shares, a steady declining curve of world wide blindness is also expected, however, best wishes for all.
Source: AP
Filed under Eye Care Products, Eye Treatment | Tags: Aurobindo Pharma Ltd., Bausch & Lomb, eye, eye care, generic drugs, ophthalmic solution, ophthalmic suspension, Ophthalmology, Pfizer Inc., vision impairment | Comment Below
Related?
Fusarium Keratitis Fungal Infection - ReNu Contact Lens Solution Link Confirmed By Bausch and LombMay 5th, 2006 Bausch
Bausch & Lomb Facing US. Federal Lawsuit Over ReNu Contact Lens SolutionApril 18th, 2006 A widely used Bausch & Lomb contact lens solution was pulled from major US retailers' shelves on Thursday at the urging of the company, as a lawsuit was filed charging that it failed to disclose the product's link to serious eye infections among users in Asia. Parker and Waichman, a high-profile New York law firm that has successfully sued several drug companies, said it had been retained by a 53-year-old man who claims to have suffered serious damage to his sight.
Bausch & Lomb's pink eye drug likely to get FDA recommendationDecember 6th, 2008 Bausch & Lomb's pink eye drug besifloxacin is currently is likely to get recommended by the FDA. Its Dermatologic and Ophthalmic Drugs Advisory Committee voted to recommend approval for besifloxacin 0.6.
Bausch & Lomb Permanently Removes ReNu With MoistureLoc Product WorldwideMay 17th, 2006 According to U.S. drug regulator FDA, contact lens maker Bausch & Lomb has finally decided to permanently withdraw its lens solution "ReNu with MoistureLoc" from global market after more evidence linked it with Fusarium infection in eye.
Fusarium Keratitis (Contact Lens Fungal Infection) Linked To ReNu Contact Lens Solution From Bausch & LombApril 12th, 2006 Bausch & Lomb voluntarily suspended shipment of a contact lens solution after federal health officials linked it to a fungal eye infection that can cause temporary blindness. The Centers for Disease Control and Prevention is investigating 109 reports of Fusarium keratitis infection in patients in 17 states since June 2005.
Law Firm Files Individual & Class Action Suit Against Bausch & Lomb as a Result of Potentially Blinding Fungal InfectionJune 1st, 2006 The Hodkin Kopelowitz Ostrow Firm, P.A. (THKO) announced that it filed a federal class action lawsuit last week in Fort Lauderdale, Florida, against Bausch & Lomb, Inc.
Bausch & Lomb Facings Class Action Lawsuit for Fusarium Kerititus - Renu LinkApril 24th, 2006 The lawsuit, filed Friday in U.S. District Court in Tampa, says the Rochester, N.Y.-based company's contact lens solution caused Helen Hreen to develop an eye infection that required medical treatment to prevent serious damage.
Basuch & Lomb (Fusarium Keratitis Fiasco) Was Cited in 2002 for Quality Control ProblemsApril 19th, 2006 Basuch & Lomb, at the center of a probe into several cases of eye fungal infection due to fusarium keratitis, was cited by the federal Food and Drug Administration for quality-control problems in 2002. During inspections in May and June 2002 at Bausch & Lomb’s Greenville, S.C., plant, the FDA discovered paint chips in rooms where containers of eye care products were filled.
